| Reported currency millions | FY2020 · USD | FY2021 · USD | FY2022 · USD | FY2023 · USD | FY2024 · USD | FY2025 · GBP | Trend | YoY |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Cost of revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Research & development | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | |
| Selling, general & administrative | 0.6 | 0.7 | 0.4 | 0.8 | 0.6 | — | — | |
| Selling & marketing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | |
| Operating expenses | 0.9 | 7.7 | 17.8 | 7.8 | 0.9 | 0.8 | −16.9% | |
| Operating income | (0.9) | (7.7) | (17.8) | (7.8) | (0.9) | (0.8) | +16.9% | |
| Interest expense | 0.0 | 0.3 | 2.3 | 1.8 | 1.2 | 1.0 | −19.4% | |
| Interest income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Other income / expense | (0.0) | (0.4) | (3.0) | (1.8) | (2.4) | — | — | |
| Pre-tax income | (1.0) | (8.1) | (20.8) | (9.6) | (3.3) | (2.0) | +39.2% | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −25.4% | |
| Net income | (1.0) | (8.1) | (20.8) | (9.6) | (3.4) | (2.0) | +39.2% | |
| Discontinued operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | |
| Other net income adjustments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | |
| EPS, basic (per share) | (2.01) | (14.33) | (27.21) | (9.85) | (0.00) | (0.00) | +77.8% | |
| EPS, diluted (per share) | (2.01) | (14.33) | (24.57) | (9.85) | (0.00) | (0.00) | +77.8% | |
| EBITDA | (0.9) | (1.6) | (18.5) | (0.9) | (0.6) | (0.8) | −20.9% | |
| Depreciation & amortization | 0.0 | 0.8 | 0.0 | 0.8 | 0.6 | — | — | |
| Weighted average shares (shares) | 479,537 | 565,853 | 764,215 | 973,296 | 2,415,094 | 5,284,638,468 | +218717.1% | |
| Weighted average diluted shares (shares) | 479,537 | 565,853 | 846,406 | 973,223 | 2,415,094 | 5,284,638,468 | +218717.1% |
Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.
Reporting currencies differ or are unavailable; each column identifies its currency.
